Biotech Investor Adds $3 Million to Krystal Biotech

Krystal Biotech revenue reaches $389 million in 2025

Published on Feb. 22, 2026

Got story updates? Submit your updates here. ›

Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing. Krystal Biotech, a biotechnology company focused on innovative gene therapy solutions for rare skin diseases, reported $389.1 million in full-year 2025 product sales, with a gross margin at 94% and net income of $204.8 million.

Why it matters

This investment by Redmile Group, a prominent biotech investor, highlights the growing confidence in Krystal Biotech's commercial success and pipeline potential. Krystal Biotech's ability to generate significant revenue and profitability in the rare disease gene therapy space is noteworthy, as profitable biotechs are relatively rare.

The details

According to the SEC filing, Redmile Group increased its position in Krystal Biotech by 16,317 shares, with the estimated transaction value of $3.43 million. This net purchase has increased Redmile's total stake in Krystal Biotech to 12.3% of its 13F-reportable assets under management. Krystal Biotech's lead product, beremagene geperpavec (B-VEC), is in late-stage clinical trials for the treatment of dystrophic epidermolysis bullosa, a rare and serious skin disease.

  • Redmile Group reported the share purchase in its February 17, 2026, SEC filing.
  • Krystal Biotech reported $389.1 million in full-year 2025 product sales.

The players

Redmile Group

A prominent biotech investor that increased its position in Krystal Biotech.

Krystal Biotech

A biotechnology company focused on innovative gene therapy solutions for rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Got photos? Submit your photos here. ›

The takeaway

This investment by a major biotech investor in Krystal Biotech, coupled with the company's strong financial performance and pipeline progress, suggests that the gene therapy firm is well-positioned to address significant unmet medical needs in the rare disease space and establish a leadership position in this growing market.